Hemodialysis, Renal Impairment
Conditions
Keywords
renal impairment, hemodialysis, Kidney failure, end-stage renal disease, Fibrodysplasia ossificans progressiva
Brief summary
This is a multicenter, open-label parallel-group to evaluate single oral doses of INCB000928 in participants with varying level of renal function or impairment.
Interventions
DRUGINCB000928
INCB000928 200 mg will be administered on Day 1 of each treatment period.
Sponsors
Incyte Corporation
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 82 Years
Healthy volunteers
Yes
Inclusion criteria
* Age 18 to 82 years (inclusive) at the time of signing the ICF. * Participants will be classified at screening by renal function based on eGFR as calculated by the MDRD formula and requirement for HD (Group 5). * Participants eligible for Group 5 with ESRD have received HD for at least 3 months prior to screening. * Participants eligible for Group 1 should be in good health as determined by no clinically significant deviations from normal for medical history, physical examination, vital signs,12-lead ECGs, or clinical laboratory determinations at screening or Day -1. * Participants eligible for Groups 2 through 5 may have medical findings consistent with their degree of renal dysfunction, as determined by medical history, physical examination, vital signs, 12-lead ECGs, and clinical laboratory determinations at screening and Day -1 (Groups 2 through 4) or Period 1, Day -1 (Group 5). Participants with abnormal findings considered not clinically significant by the medical monitor or investigator are eligible. * Body mass index within the range 18.0 to 40.0 kg/m2 (inclusive) at screening. * Willingness to avoid pregnancy or fathering children based on the criteria defined in the protocol. * Ability to swallow and retain oral medication.
Exclusion criteria
* History of uncontrolled or unstable cardiovascular, respiratory, hepatic, GI, endocrine, hematopoietic, psychiatric, and/or neurological disease within 6 months of screening. * Evidence of rapidly deteriorating renal function. * Participants who have a current, functioning organ transplant or have a scheduled organ transplant within 6 weeks after check-in. * History of malignancy within 5 years of screening, with the exception of cured basal cell carcinoma, squamous cell carcinoma of the skin, ductal carcinoma in situ, or Gleason 6 prostate cancer. * History of clinically significant GI disease or surgery (cholecystectomy and appendectomy are allowed) that could impact the absorption of study drug. * Participants eligible for Group 1 who have a history of renal disease or renal injury as indicated by an abnormal, clinically significant renal function profile at screening or Day -1. * Participants eligible for Groups 2 through 5 who have had a change in disease status within 30 days of screening, as documented by the participant's medical history and deemed clinically significant by the investigator. * History or current diagnosis of uncontrolled or significant cardiac disease indicating * significant risk of safety for participation in the study, including any of the following: 1. Recent myocardial infarction (within 6 months of check-in). 2. New York Heart Association Class III or IV congestive heart failure. 3. Unstable angina (within 6 months of check-in). 4. Clinically significant (symptomatic) cardiac arrhythmias (eg, sustained ventricular tachycardia, second or third degree atrioventricular block without a pacemaker). 5. Uncontrolled hypertension. * Any major surgery within 4 weeks of screening. * Donation of blood to a blood bank within 4 weeks of screening (within 2 weeks for * plasma only). * Blood transfusion within 4 weeks of Day -1 (for Groups 1 through 4) or Period 1, * Day -1 (Group 5). * Chronic or current active infectious disease requiring systemic antibiotic, antifungal, or antiviral treatment. * Positive test and symptomatic for HBV, HCV, or HIV. Participants whose results are compatible with prior immunization for or immunity due to infection with HBV may be included at the discretion of the investigator. * Participants eligible for Group 1 who have a history of using tobacco- or nicotine containing products within 6 months of screening. * Participants eligible for Groups 2 through 5 who smoke \> 10 cigarettes per day or equivalent use of other tobacco- or nicotine-containing products and are unwilling to refrain from tobacco or nicotine use on dosing days and abide by CRU restrictions. * History of alcohol dependency within 3 months of screening. * Positive breath test for ethanol or positive urine or saliva screen for drugs of abuse (confirmed by repeat) at screening or check-in that are not otherwise explained by permitted concomitant medications. * Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) of study drug administration with another investigational medication or current enrollment in another investigational drug study. * Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) of study drug administration with strong or moderate inducer or inhibitor of CYP3A4 or P-gp (refer to the Drug Interaction Database Program \[University of Washington School of Pharmacy 2002\] for prohibited drugs). * Participants eligible for Group 1 who have used prescription drugs within 14 days of study drug administration or nonprescription medications/products (including vitamins, minerals, and phytotherapeutic/herbal/plant-derived preparations) within 7 days of study drug administration. However, occasional acetaminophen and ibuprofen are permitted. * Participants eligible for Groups 2 through 5 who have used prescription drugs within 14 days of study drug administration, with the exception of established therapy for renal disease and the treatment of associated disorders that have been stable for at least 7 days prior to study drug administration, as approved by the investigator and in consultation with the sponsor's medical monitor. * Current or recent history (within 30 days before screening) of a clinically significant bacterial, fungal, parasitic, or mycobacterial infection, or currently receiving systemic antibiotics. Current clinically significant viral infection at screening or check-in. * History of any significant drug allergy (such as anaphylaxis or hepatotoxicity) deemed clinically relevant by the investigator. * Inability to undergo venipuncture or tolerate venous access. * Participants eligible for Group 5 who are not expected to continue HD treatment for the duration of the study. * Receipt of live (including attenuated) vaccines within 3 months of check-in or * anticipation of need for such a vaccine during the study (Note: nonlive or inactivated vaccines are allowed up to 2 weeks prior to the first dose of study drug). * Known hypersensitivity or severe reaction to INCB000928 or excipients of INCB000928(refer to IB). * Inability or unlikeliness of the participant to comply with the dose schedule and study evaluations, in the opinion of the investigator. * Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits;pose a significant risk to the participant; or interfere with interpretation of study data. * Women who are pregnant or breastfeeding. * QTc \> 450 milliseconds for Groups 1 through 3 and QTc \> 470 milliseconds for Group 4. * Participants eligible for Group 1 who have abnormal LFT values, defined as aspartate aminotransferase, alanine aminotransferase, and serum (total and direct) bilirubin, as well as amylase and lipase above the upper limit of the normal range at screening. * Participants eligible for Groups 2 through 4 who have values outside the normal ranges for LFTs; however, values may be acceptable if they are consistent with the participant's renal condition (if stable for 1 month prior to screening) and if the investigator (or designee) and the sponsor feel that the results are not clinically significant (based on age and renal impairment status).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PK for plasma of INCB000928: Cmax | Days 1 - 4 | Defined as maximum observed plasma or serum concentration, this test will assess the effect of renal impairment and hemodialysis on the exposure of single oral doses of INCB00928 |
| PK for plasma of INCB000928: AUC0-t | Days 1 - 4 | Defined as area under the steady-state plasma or serum concentration-time curve over 1 dose interval, this test will assess the effect of renal impairment and hemodialysis on the exposure of single oral doses of INCB00928. |
| PK for plasma of INCB000928: AUC0-∞ | Days 1 - 4 | Defined as area under the single-dose plasma or serum concentration-time curve extrapolated to time of infinity, this test will assess the effect of renal impairment and hemodialysis on the exposure of single oral doses of INCB00928. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PK for plasma of INCB000928: CL/F | Days 1 - 4 | Defined as apparent oral dose clearance |
| Number of treatment-related adverse events | Days 1-4 and follow up; up to 14 days | To determine the safety and tolerability of INCB000928 administered as monotherapy in participants with with impaired renal function and hemodialysis. |
| PK for plasma of INCB000928: AUC3-7 | Days 1 - 4 | Group 5 only: Defined as area under the plasma or serum concentration-time curve from 3 to 7 h during dialysis, Period 1. |
| PK for plasma of INCB000928: Vz/F | Days 1 - 4 | Defined as apparent oral dose volume of distribution |
| PK for plasma of INCB000928: tmax | Days 1 - 4 | Defined as time to maximum concentration |
| PK for plasma of INCB000928: t½ | Days 1 - 4 | Defined as apparent terminal-phase disposition half-life |
Countries
United States
Outcome results
None listed